A phase 3 study of eftilagimod alfa for NSCLC is ending early due to futility, according to an update from developer Immutep.

Independent Data Monitoring Committee Recommends Discontinuation of Phase III Trial Following Futility Analysis SYDNEY, AUSTRALIA, March 13, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: ...

Immutep (IMMP) stock plummeted 80% after the company halted its Phase III NSCLC trial for futility, triggering analyst downgrades and massive selling.

Ipsen telegraphed plans to acquire Epizyme and the FDA-approved Tazverik in June 2022, two years after the med’s clearance in the U.S. as both an epithelioid sarcoma and follicular lymphoma treatment.

Ipsen initiated an immediate, worldwide withdrawal of the EZH2 inhibitor tazemetostat across follicular lymphoma and epithelioid sarcoma due to emerging safety signals. An independent data monitoring ...

UT earmarks ₹80 lakh for four new real-time stations in industrial hubs; move aimed at addressing data blind spots in South Kashmir and Jammu.

Kivo reports that the journey of prescription drugs involves extensive research, clinical trials, regulatory reviews, and ...

Ipsen has pulled Tazverik from all markets after a trial found risks of secondary blood cancers, affecting patients with follicular lymphoma and epithelioid sarcoma.

As part of these efforts, mechanical road sweeping machines have been introduced in several areas to reduce dust levels.

Researchers told Iowa House lawmakers Wednesday that legislation raising taxes on tobacco and implementing more pesticide monitoring requirements could help lower the state’s high cancer rates and ...

This story is courtesy of the Vilas County News Review. Vilas and Oneida counties have received more than $1.1 million in ...

With anger stoked by Channel 4’s drama Dirty Business, we look at what has happened to some of the main players ...